Objective: The aim of this study was to confirm determinative factors for plasma Ab and its association with cognitive function. Methods: Fasting plasma Ab40 and Ab42 levels were measured by ELISA in 1019 participants in the Iwaki Health Promotion Project. The relationships between plasma Ab and health-related items, including physical characteristics, cognitive function tests, blood chemistry, and APOE-e4 genotype were analyzed. Results: The plasma levels of Ab40 and Ab42, and Ab40/42 ratio were found to significantly increase with aging. The age-dependent increase in Ab42 level was significantly suppressed by APOE-e4. Renal function was an associated factor for the plasma Ab40 level. The plasma Ab42 level and Ab40/42 ratio correlated with cognitive function. Interpretation: Age and APOE-e4 are major determinative factors of plasma levels of Ab42 and the Ab40/42 ratio. These factors are critical adjustment factors for the usage of plasma Ab as a biomarker of central nervous system amyloidosis.
Introduction
Alzheimer's disease (AD) is observed at a critical rate due to the aging population. The latest research suggests that it is possible to prevent pathological processes in AD by developing disease-modifying therapies, such as anti-Ab antibodies and BACE-1 inhibitors, against Ab amyloidosis, which act on pathological cascades, including tauopathy. Prospective cohort studies have reported that the ratio of Ab40/42 is significantly associated with late-life cognitive decline, 1 and risk of developing MCI and AD. [2] [3] [4] [5] [6] Systematic reviews and meta-analyses have also suggested that the plasma Ab40/42 ratio can predict the development of AD and dementia. 7 However, these findings indicated significant heterogeneity, 7 and plasma levels of Ab40 and Ab42 alone were not significantly associated. 8, 9 The Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN) have confirmed the efficacy of neuropsychiatric tests and neuroimaging using cerebrospinal fluid (CSF) biomarkers, including amyloid PET, demonstrating that signatures of brain Ab amyloidosis can be found approximately 30 years before the onset of dementia.
Recent studies have clarified that the plasma Ab42/40 ratio is inversely correlated with cortical amyloid burden in AD, which can be converted into MCI, 12, 13 and that the plasma Ab42/40 ratio is a useful screening marker for brain Ab amyloidosis in normal individuals. 14, 15 Approximately 30-50% of Ab in the plasma originates from the brain. 15 Age, APOE-e4, and AD pathology are specific determinants of Ab turnover kinetics from the brain to CSF, and finally to plasma. 15, 16 We therefore focused on determinant factors of plasma Ab levels. As Ab amyloidosis initiates midlife, it is necessary to analyze these factors in large communitybased studies on young adolescent to elderly subjects. Age and APOE-e4 are two major factors accelerating CNS amyloidosis leading to the onset of AD dementia. 17 The gene dose of APOE-e4 may decrease plasma Ab42 levels with natural aging, or long-term preclinical stage of AD dementia. 10, 17 For this reason, basic information on how plasma Ab levels are regulated over time by blood biochemical factors, cognitive function, and lifestyle remains to be clarified in order to adjust plasma Ab levels for CNS amyloidosis-specific markers. 18, 19 Here, we analyzed definite factors of plasma Ab of participants in The Iwaki Health Promotion Project (IHPP) in 2014, a community-based annual health checkup study designed to prevent and improve lifestyle-related diseases and quality of life.
Materials and Methods

Subjects
A total of 1109 participants with complete data sets out of 1167 enrolled participants were analyzed. The age of 619 participants ranged from 19 to 59 years (mean age of 54 years; 365 females) and 490 participants were older than 60 years of age (mean age of 68 years; 323 females). The baseline characteristics of participants are presented in Table 1 . Clinical diagnoses of dementia, Alzheimer dementia (AD), and mild cognitive impairment (MCI) were based on the NIA-AA clinical criteria. 20, 21 A total of 200 medical and paramedical staff examined participants between 6:30 to 13:00 over 10 days at Iwaki culture center. After written informed consent, a mini-mental state examination (MMSE) for all participants, the logical memory II tests (delayed recall: LM-II) from the Wechsler Memory Scale-Revised (WMS-R), and a detailed questionnaire for memory disturbances and ADL conditions were performed for participants older than 60 years of age. During and after these items, medical and neurological examinations, motor performance, blood pressure, height, body weight, BMI, and body fatty ratio (BFR) were evaluated, and common laboratory tests were performed for complete blood cell count, nutrition, liver and renal function, diabetes mellitus, cholesterol and lipid metabolism, endocrine system, immunology, cardiovascular biomarkers, and urine analysis (details in Tables S1  and S2 ).
Ab40 and Ab42 Quantitation
Ten milliliters of morning fasting blood was taken into an EDTA-2Na tube and immediately centrifuged at 1400 g for 10 min, separated to plasma in a polypropylene tube, and stored frozen at À80°C until use. Sandwich ELISA was used to quantify plasma Abx-40 and Abx-42 levels using a Human/Rat b Amyloid (40) ELISA Kit Wako II and a Human/Rat b Amyloid (42) ELISA Kit Wako High-Sensitive (Wako Pure Chemical Industries, Ltd, Osaka, Japan). 22, 23 Microplates were precoated with monoclonal BNT77 (IgA, anti-Ab11-28, specific for Ab11-16) and sequentially incubated with 25 lL of samples, followed by application of horseradish-peroxidaseconjugated BA27 (anti-Ab1-40, specific for Ab40) or BC05 (anti-Ab35-43, specific for Ab42/43). The sensitivity was 0.049 pmol/L (assay range 1.0-100 pmol/L) in the Ab40 assay and 0.024 pmol/L (assay range 0.01-20.0 pmol/L) in the Ab42 assay. Intra-and interassay coefficients of variation were less than 10% for both Ab40 and Ab42. After excluding samples with mean values over +3 standard deviation by Grubbs' method, 24, 25 1091 assay values were analyzed.
APOE genotyping
DNA of 1,151 Iwaki residents was purified from peripheral whole blood using the QIAamp â 96 DNA Blood Kit (QIAGEN, Hilden, Germany), and APOE genotype was determined by Toshiba corporation using the Japonica Array consisting of population-specific SNP markers designed from the 1070 whole genome reference panel. 26, 27 Fifty-three samples that were not determined by the microarray analysis were genotyped by direct sequencing by the Greiner corporation using the following primer set: Forward primer; 5 0 TGG ACG AGA CCA TGA AGG AGTT and reverse primer; CAC CTG CTC CTT CAC CTC GTCCA, except for 11 samples that we analyzed using the following primer set: Forward primer; 5 0 TGG ACG AGA CCA TGA AGG AGT and reverse primer; CAC CTG CTC CTT CAC CTC GTCCA.
Statistical analysis
Plasma Ab40, Ab42, Ab40/42 ratios did not deviate significantly from normal distribution according to the histograms. To clarify the relationships between plasma Ab levels and other factors, including blood examination data, life style, and motor functions, correlation analysis was used. For comparison of normal distribution factors, Pearson's correlation coefficient analysis was applied. If normalization was not possible, Spearman's rank correlation coefficient analysis was used. To examine the effects on plasma Ab by aging, linear regression models were used. To plot the age-dependent changes in plasma Ab, the simple linear regression model was applied, and the linear regression line was drawn by the method of least squares. To compare the significance between the slopes of the linear regression models and to adjust for confounding factors, multiple regression analysis was applied. To examine whether Ab and cognitive function are related, we compared the plasma Ab levels between the high MMSE scores group (29 or 30) and low MMSE scores (less than 29) in subjects aged 60 years and over. In this group comparison, multiple logistic regression was used to adjust for age. Two-tailed P-values less than 0.05 were considered significant. These analyses were performed with IBM SPSS Statistics, version 24 (IBM Japan, Tokyo) and GraphPad Prism, version 7 (GraphPad Software, San Diego, CA). In this study, statistical analyses were conducted with all 1019 participants, including 991 normal, 26 MCI, and 2 AD dementia individuals.
Results
Plasma Ab Levels and relationship with APOE genotype
The meanAESD of the Ab40 plasma level was 106.2 AE 15.5 pmol/L, that of the Ab42 level was 11.36 AE 1.7, and that of the Ab40/42 ratio was 9.42 AE 1.1 in all participants. A significant linear increase with age was observed for Ab40 levels (Y = 0.4724X + 79.65, r 2 = 0.2208, P < 0.0001), Ab42 levels (Y = 0.02466X + 10.04, r 2 = 0.04898, P < 0.0001), and the Ab40/42 ratio (Y = 0.02234X + 8.113, r 2 = 0.09725, P < 0.0001) (Fig. 1A-C) .
To evaluate whether the APOE-e4 alleles affect plasma Ab levels, age-dependent changes in plasma Ab levels between APOE-e4 carriers and noncarriers were analyzed. Age-dependent increases in Ab40 levels were observed in both non-APOE-e4 allele carriers (Y = 0.4619X + 80.29, r 2 = 0.2163, P < 0.0001) and APOE-e4 carriers (Y = 0.5153X + 77.08, r 2 = 0.2389, P < 0.0001). Ab42 levels were increased in noncarriers (Y = 0.02984X + 9.842, r 2 = 0.07497, P < 0.0001) but not in APOE-e4 carriers (Y = 0.0001912X + 10.92, r 2 = 0.00002616, P = 0.8068) with aging. The Ab40/42 ratios were increased both in noncarriers (Y = 0.01701X + 8.327, r 2 = 0.066, P < 0.0001) and carriers (Y = 0.04561X + 7.159, r 2 = 0.2658). Plasma Ab40 and Ab42 levels, and the Ab40/42 ratio increased with aging, except for Ab42 levels in APOE-e4 carriers by simple linear regression ( Fig. 2A-F) .
After adjusting for total protein, platelet count, and creatinine levels, which were previously reported as confounding factors for plasma Ab levels, 18, 19 the multiple linear regression model was used to clarify whether the age-dependent increases in Ab levels were affected by APOE-e4. There were significant differences between carriers and noncarriers in regression lines of Ab42 (P < 0.0001) and Ab40/42 (P < 0.0001) but not Ab40 (P = 0.76) (Fig. 3A-B , details in Table S3 ). To further validate these results, multiple linear regression model analyses were performed after adjustments for hemoglobin, platelet count, albumin, creatinine, blood urea nitrogen, fasting plasma glucose (FPG), free fatty acid, hemoglobin A1c, and cystatin C, which were all found to be correlated with both plasma Ab40 and Ab42 levels in our study. There were also significant differences between carriers and noncarriers in regression lines of Ab42 (P = 0.001) and Ab40/42 (P < 0.0001) but not Ab40 (P = 0.923) (details in Table S4 ). Thus, the agedependent increases in Ab42 levels were suppressed by APOE-e4, whereas age-dependent increases in the Ab40/ 42 ratio were enhanced by APOE-e4.
Association between MMSE scores and plasma Ab levels
Subjects aged 60 years old and over were separated into high MMSE score (30, 29 points; n = 340) or low MMSE score (less than 28 points; n = 150) groups. Plasma Ab40, Ab42, and Ab40/42 ratio levels were plotted, and an asterisk was plotted when there were significant differences between the two groups on multiple logistic regression analyses after adjusting for age (Fig. 4A-C) . There was no significant difference in variables for Ab40 levels (P = 0.25). However, significant differences in variables for both age and Ab42 were observed for Ab42 (P < 0.0001 and P = 0.04), and also by the model chi-squared test (P < 0.0001). The Hosmer-Lemeshow test demonstrated good predictability (P = 0.502), with a discrimination predictive value of 69.0%. On analysis of the plasma Ab40/42 ratio, there were significant differences in both age and Ab ratio (<0.0001 and P = 0.046), and by the model chi-squared test (P < 0.0001). Predictability was good (P = 0.502), with a discrimination predictive value of 70.2% (details in Table S5 ). There were no significant differences in Ab concentrations between "AD and MCI group" and "randomly selected age and APOE genotype-matched high MMSE score group (28 participants)". Each P value was ) and regression equations are shown (N = 1109). Significant linear increases with age were observed for plasma Ab40 and Ab42 levels, and Ab40/42 ratio (A-C). Figure 2 . APOE-e4 suppresses age-dependent plasma Ab increases. Analyses of the age-related plasma Ab changes were performed for APOE-e4 carriers and noncarriers separately. Age-dependent increases in Ab40 levels and the Ab40/42 levels were observed in both noncarriers (A, C) and APOE-e4 carriers (D, F). Levels of Ab42 were increased in noncarriers but not in APOE-e4 carriers with aging (B, E). 
Factors affecting plasma levels of Ab
Although the other blood chemistry test items were found to have significant linear correlations with Ab levels, the correlation coefficients were very low. A strong correlation was only noted between cystatin C levels and Ab40 levels (r = 0.5276). These results are shown in Tables S1 and S2. We additionally analyzed the correlation between plasma Ab levels and habits or physical conditions. Weak correlations between both Ab40 and Ab42 levels, and alcohol intake, smoking amount, body fat ratio, and muscle mass were observed. Measurements of four major complex motor reaction tests, including the ruler drop test, timed up and go test, 10 m walk test, and wholebody reaction time test, were more associated with plasma Ab40 and Ab42 levels than simple muscle strength, but the correlation coefficients were low. Figure 3 . APOE-e4 alters age-dependent Ab42 levels and Ab40/42 ratio. The regression lines for age-related plasma Ab42 and the Ab40/42 ratio in APOE-e4 carriers and noncarriers were merged. There were significant differences between carriers and noncarriers in regression lines for Ab42 (A) and Ab40/42 (B) after adjusting for total protein, platelet count, and creatinine levels. . Correlation between MMSE scores and plasma Ab levels. Comparison of plasma Ab levels between high MMSE score and low MMSE score groups of subjects aged 60 years and over. There were significant differences (*) between the two groups in Ab42 levels and the Ab40/42 ratio on multiple logistic regression analyses after adjusting for age (A-C). 
Discussion
Our results demonstrated the following: (1) Fasting plasma levels of Ab40 and Ab42, and the Ab40/42 ratio age-dependently increased from 20 years old. (2) The presence of APOE-e4 suppressed these age-dependent increases in plasma Ab42 levels. (3) Age and APOE-e4 were most significant factors for plasma Ab42 levels and Ab40/42 ratios after adjusting for previously indicated and newly examined factors, including blood chemistry, life style, and activity. (4) Only renal function was a definitive factor for plasma Ab40 levels. (5) Plasma Ab42 levels and Ab40/42 ratios were correlated with lower MMSE scores in subjects aged over 60 years.
With a longer follow-up, repeated measurement of plasma Ab may be useful as a simple and minimally invasive screening procedure to detect brain Ab amyloidosis. [14] [15] [16] Ab in plasma does not only originate in the brain because it is also involved in amyloid precursor protein (APP) metabolism in peripheral organs, it binds to several proteins and lipoproteins, is partially released from activated platelets, and is metabolized in the liver and cleared through the kidneys. 19 However, a recent study suggested that 30-50% of plasma Ab originates from the CNS. 15 APOE-e4 is the strongest genetic risk factor for sporadic late onset AD, and markedly accelerates Ab amyloid deposition in the brain and the onset age of dementia by approximately 10 years. 10, 17 Recent studies have revealed that CNS-derived Ab is cleared into the CSF 28 and peripheral blood, 29 and that the clearance rate is decreased in late onset AD, 30 and is differently regulated by age and presence of Ab amyloidosis. 15, 31 Association of plasma Ab levels and cortical amyloid burden is also modulated by APOE isoforms. 32 Together with these data, our findings that aging and APOE-e4 are critical factors for plasma Ab42 levels from 20 years of age are consistent with Ab42 clearance from the brain to peripheral plasma. For this reason, adjustments of the plasma Ab42 level and Ab40/42 ratio for age, and APOE-e4 allele at any age are essential for evaluating plasma Ab levels as biomarkers of the progress of brain Ab amyloidosis or clinical trials of disease modifying drugs.
Technical problems, including storage tubes, temperature, periods, buffers, and pipetting, during the assay procedure affect plasma Ab levels. 27 Sleep-wake cycles of Ab production and clearance also affect CNS Ab levels. 33 We carefully managed fasting morning blood sampling, storage, and assay procedures, and obtained intra-and interassay coefficients with a variation of less than 10% in both Ab40 and Ab42 assays. We then analyzed the correlations among plasma Ab and other blood factors. In the ADNI cohort, platelet count, creatinine, and total protein affected plasma Ab levels. 18, 19 However, the IHPP cohort comprising a wide range of age did not report similar findings. Creatinine levels were correlated with plasma Ab40 and Ab42 as well as previous study. 18, 34 The present study demonstrated a strong correlation between plasma Ab40 and cystatin C levels. Cystatin C may respond to plasma Ab and renal function more sensitively than creatinine. Higher LDL-C and Lower HDL-C levels were both associated with cerebral amyloidosis 35 but not with late life cholesterol or AD neuropathology. 36 Our results suggested that serum cholesterol levels are not directly corrected with plasma Ab levels. Type 2 diabetes mellitus is a well-known risk factor for AD. Type 2 diabetes is positively associated with CSF Ab42, but negatively associated with cerebral cortical Ab burden. 37 Although a few large scale-studies have reported an association between glucose metabolism and plasma Ab by strict sampling of morning fasting blood, we found no correlation among plasma Ab levels, FPG, hemoglobin A1c, and glycoalbumin, indicating no direct relationship between plasma Ab and blood glucose levels. In conclusion, there were no strong determinant factors directly related with plasma Ab levels, except Cystatin C for Ab40 level, in the IHPP cohort.
Regarding the relationship between plasma Ab and lifestyle, no direct association was found with systolic or diastolic blood pressure, 38, 39 nor with alcohol intake, hours of sleep or smoking amount by questionnaire survey. Physical and motor activity, including 10MWT, RDT, TUG, and WBRT as candidates for integrated cognitive processes that require attention, planning, visuospatial, and motor processes, demonstrated linear associations with the plasma Ab40/42 ratio. However, these correlation coefficients were weak, suggesting that plasma Ab40/42 is not a predictor for complex motor activity related with cognitive function. 40 Prior major cohort studies have reported that plasma Ab is a risk factor or predictive marker for AD onset in healthy older community members aged at least 55 years. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In contrast, after analyzing fasting blood samples from healthy individuals of a wide age range, we observed the natural course of and factors affecting plasma Ab40 and Ab42. The period from mid-life to elderly is critical for preclinical progression of Ab amyloidosis. Consistent with other reports, we found that decreased plasma Ab42 levels and increased Ab40/42 ratio were associated with low cognitive ability in participants aged over 60 years. Furthermore, plasma Ab42 levels were stably regulated mainly by age and APOE-e4. As this study was cross-sectional, we were unable to validate plasma Ab42 and Ab40/42 ratio as a predictive biomarker for the onset of AD. This is one limitation of our study. Furthermore, we were also unable to analyze the association between Ab and vascular factors by MRI. To resolve these limitations, longitudinal confirmation is necessary. To confirm this basic data from the 2014 study, we are repeating the same annual surveys from 2015 to 2017, to clarify the factors of plasma Ab and evaluate plasma Ab40 and Ab42 as biomarkers of onset of Ab amyloidosis in the brain.
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